Gut Microbiome in DLBCL Treated With Glofitamab

Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With Glofitamab

The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.

This is a prospective observation study to evaluate the role of gut microbiome in DLBCL patients treated by glofitamab.

Inclusion Criteria:

1. Histologically/cytologically confirmed diagnosis of DLBCL
2. Is being planned to received Glofitamab
3. Be able to provide written informed consent

Exclusion Criteria:

1. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results.
2. Concurrent second malignancy.